Clinical study of remimazolam in obese patients undergoing gastric volume reduction surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065602

Enrollment

Unknown

Registered

2022-11-09

Start date

2022-11-25

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obese

Interventions

group 1:intravenous remimazolam with fixed dose of sufentanil

group 2:Remifentanil (TCI target concentration 3ng/ml) and remimazolam were used for intravenous maintenance

group 3:Remifentanil (TCI target concentration 5ng/ml) and remimazolam were used for intravenous maintenance

group 4:Remifentanil (TCI target concentration 7ng/ml) and remimazolam were used for intravenous maintenance

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Obese patients undergoing laparoscopic sleeve gastrectomy,BMI: 28-40, undergoing routine induction of tracheal intubation,ASA ? - ?, aged 18-60 years,signed the informed consent form for clinical trial.

Exclusion criteria

Exclusion criteria: Refusing to participate in clinical trials, poor preoperative control of hypertension, chronic heart failure, respiratory failure, obvious abnormal liver and kidney functions, Malampati IV, difficult mask ventilation, preoperative cognitive dysfunction.

Design outcomes

Primary

Measure	Time frame
OAA/S score;	—

Secondary

Measure	Time frame
blood pressure and heart rate;	—

Countries

China

Contacts

Public ContactChen Minghui

Department of Anesthesia, Shanghai Tenth People's Hospital,

cmhkeky@126.com+86 15921350209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026